# KEYNOTE-122 (NCT02611960)

> Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: platinum pre-treated recurrent or metastatic nasopharyngeal cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02611960
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Nasopharyngeal Neoplasms
- Interventions: Pembrolizumab; Capecitabine; Gemcitabine; Docetaxel
- Enrollment: 233
- Primary outcome: Overall Survival (OS)

## Indexed commentary on KEYNOTE-122 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 YouTube videos
- 2 podcast episodes
- 1 post on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=keynote-122-nct02611960